Tag: AMD

- XIPERE Now Approved for Use in Multiple Global Markets -

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of July 2025 for its open-end exchange traded funds and closed-end funds (“the Funds”).

TORONTO, 18 juill. 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (« Purpose ») a le plaisir d’annoncer des distributions pour le mois de de juillet 2025 pour ses fonds négociés en bourse à capital variable et ses fonds à capital fixe (les « Fonds »).

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

According to Precedence Research, the global semiconductor market size was valued at USD 584.17 billion in 2024 and is projected to be worth around USD 1.2 trillion by 2034, reflecting a solid CAGR of 7.54% from 2025 to 2034.

ETX-312 wurde in GLP-konformen Toxikologiestudien in überhöhten Dosierungen gut vertragen

SANTA CLARA, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) announced today that it will report fiscal second quarter 2025 financial results on Tuesday, Aug. 5, 2025, after the market close. Management will conduct a conference call to discuss these results at 5:00 p.m. EDT / 2:00 p.m. PDT. Interested parties are invited to listen to the webcast of the conference call via the AMD Investor Relations website ir.amd.com.

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.